Washington, D.C. 20549






Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of June, 2022

Commission File Number 001-39670




(Translation of registrant’s name into English)



6 Tide Street, Suite 400

Boston, Massachusetts 02210

(Address of principal executive office)



Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐





On June 15, 2022, PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (the “Company”) issued a press release announcing the results of its 2022 Annual General Meeting. The full text of the resolutions may be found in the Notice of the Annual General Meeting, copies of which are available on both the Company’s website https://investors.puretechhealth.com/financials-filings/reports and on the National Storage Mechanism.

The press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.



99.1    Press Release of PureTech Health plc, dated June 15, 2022, titled “Results of Annual General Meeting.”


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Date: June 15, 2022     By:  

/s/ Daphne Zohar

      Name: Daphne Zohar
      Title: Chief Executive Officer

Exhibit 99.1

15 June 2022

PureTech Health plc

Results of Annual General Meeting

The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech Health” or the “Company”) was held at 11 a.m. EDT/4 p.m. BST on Wednesday, June 15, 2022.

All of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a poll.

The results of the poll, incorporating the proxy votes lodged in advance of the meeting, are set out below.



   For      %      Against      %      Withheld      Total votes

001. To approve the Company’s Annual Report and Accounts for year ended 31 December 2021

     216,387,000        100.00        0        0.00        529,458        216,387,000  

002. To approve the Directors’ Remuneration Report

     186,654,636        86.20        29,871,462        13.80        390,360        216,526,098  

003. To elect Ms. Sharon Barber-Lui as a director

     216,911,434        100.00        2,288        0.00        2,736        216,913,722  

004. To elect Dr. Raju Kucherlapati as a director

     214,260,532        98.78        2,653,190        1.22        2,736        216,913,722  

005. To elect Dr. John LaMattina as a director

     208,222,704        95.99        8,691,018        4.01        2,736        216,913,722  

006. To elect Ms. Kiran Mazumdar-Shaw as a director

     186,900,260        86.16        30,013,462        13.84        2,736        216,913,722  

007. To elect Dame Marjorie Scardino as a director

     216,877,331        99.98        37,071        0.02        2,056        216,914,402  

008. To elect Mr. Christopher Viehbacher as a director

     190,417,512        87.78        26,496,210        12.22        2,736        216,913,722  

009. To elect Dr. Robert Langer as a director

     212,747,748        98.08        4,165,974        1.92        2,736        216,913,722  

010. To elect Ms. Daphne Zohar as a director

     216,905,622        100.00        8,100        0.00        2,736        216,913,722  

011. To elect Dr. Bharatt Chowrira as a director

     216,706,444        99.90        207,278        0.10        2,736        216,913,722  

012. To reappoint KPMG LLP as Auditors of the Company

     212,180,052        97.82        4,729,435        2.18        6,971        216,909,487  

013. To authorize the Audit Committee to determine the Auditors’ remuneration

     212,703,757        98.06        4,211,701        1.94        1,000        216,915,458  

014. To authorize the allotment of shares

     212,364,212        97.90        4,551,246        2.10        1,000        216,915,458  

015. To disapply pre-emption rights

     216,589,860        99.85        324,482        0.15        2,116        216,914,342  

016. To further disapply pre-emption rights for acquisitions and specified capital investments.

     204,225,243        94.15        12,689,099        5.85        2,116        216,914,342  

017. To authorize market purchase of own shares

     216,386,703        99.76        528,755        0.24        1,000        216,915,458  

018. To authorize general meetings to be called on not less than 14 clear days’ notice

     212,326,728        97.88        4,588,730        2.12        1,000        216,915,458  




A vote “Withheld” is not a vote in law and is not counted in the calculation of the votes “For” or “Against” a resolution.



As at June 13, 2022, the record date for the Annual General Meeting, the number of issued shares in the Company entitling the holders to attend and vote for or against all the resolutions at the AGM was 287,633,591 ordinary shares. This does not include 977,529 shares held in treasury by the Company. In accordance with the Company’s Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.



The full text of the resolutions may be found in the Notice of the Annual General Meeting, copies of which are available on both the Company’s website https://investors.puretechhealth.com/financials-filings/reports and on the National Storage Mechanism.

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders.

This pipeline, which is being advanced both internally and through PureTech’s Founded Entities, is comprised of 27 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization, as of the date of PureTech’s most recently filed Annual Report and corresponding Form 6-K. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on unique insights in immunology and drug development.

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2021 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.




Investor Relations